Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 626.12% and ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding. The acquisition expands the healthcare ...

Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly worth $5 billion. The company's stock was upgraded by Deutsche Bank analysts following its ...

Eli Lilly completes acquisition of Morphic to improve outcomes for people living with inflammatory bowel disease: Indianapolis Tuesday, August 20, 2024, 16:00 Hrs [IST] Eli Lilly ...

Eli Lilly has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults ...

International drugmaker, Eli Lilly, announced plans in May to invest $5.3 billion (€4.9 billion) in a new manufacturing site ...

Analyst Akash Tewari of Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), boosting the price target to ...

Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a strategic move aimed at bolstering its inflammatory bowel disease (IBD) portfolio.

Analyst optimism lifted Eli Lilly shares in early trading, but the stock finished lower following news of a debt sale to fund ...

INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a ...